QQ客服 官方微博 反馈留言

浏览/检索结果: 共23条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Light emitting device and light emitting device package 专利 专利号: US20190019929A1, 申请日期: 2019-01-17, 公开日期: 2019-01-17 作者:  LIM, CHANG MAN;  KIM, KI SEOK;  KIM, YOUNG SHIN;  SONG, JUNE O;  OH, JU HYEON 收藏  |  浏览/下载：15/0  |  提交时间：2019/12/30 First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression 期刊论文 2019, 卷号: 145, 期号: 6, 页码: 1569-1579 作者:  Schuler, Martin;  Tan, Eng-Huat;  O'Byrne, Kenneth;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：20/0  |  提交时间：2020/01/03 Afatinib  EGFR  NSCLC  Dose adjustment  Time-to-treatment failure   Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial 期刊论文 JAMA ONCOLOGY, 2018, 卷号: 4, 期号: 9 作者:  Goss, Glenwood D.;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05 Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers 会议论文 作者:  Isla, Dolores;  Min, Young Joo;  Ardizzoni, Andrea;  Gadgeel, Shirish;  Dupuis, Nicholas 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05 Squamous cell carcinoma of the lung  NSCLC  afatinib   First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 期刊论文 2017, 卷号: 12, 期号: 1, 页码: S335-S336 作者:  Park, Keunchil;  Tan, Eng Huat;  Zhang, Li;  Hirsh, Vera;  O'Byrne, Ken 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/03 afatinib  gefitinib  NSCLC  EGFR   Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial 期刊论文 2016, 卷号: 17, 期号: 5, 页码: 577-589 作者:  Park, Keunchil;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li;  Boyer, Michael 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/04 First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm plus ) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Hirsh, Vera;  Yang, James Chih-Hsin;  Tan, Eng-Huat;  O'Byrne, Ken;  Zhang, Li 收藏  |  浏览/下载：7/0  |  提交时间：2020/01/04 Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2015, 卷号: 33, 期号: 15 作者:  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun;  Syrigos, Konstantinos N. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 A fatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial 会议论文 作者:  Gadgeel, Shirish;  Soria, Jean-Charles;  Felip, Enriqueta;  Cobo, Manuel;  Lu, Shun 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05 Lung cancer / Oncology